IL-6 Inhibitor Compounds Selective Pathway Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective and specific small molecule inhibitors for the IL-6/gp130 pathway, which is crucial in cancer and inflammatory conditions, due to the limited availability and potency of existing compounds like MDL-A and its analogues, and non-specific inhibitors like SC144.
Innovation Solution
Development of novel compounds, such as those represented by Formula (I) and their pharmaceutically acceptable salts, solvates, hydrates, or prodrugs, which selectively inhibit the homodimerization of IL-6/IL-6Rα/gp130 trimers without disrupting the IL-6/IL-6Rα/gp130 trimer formation, thereby targeting cancer and inflammatory pathways with improved specificity and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing compounds like MDL-A and its analogues are used as IL-6 inhibitors, then some inhibitory effect is achieved, but the potency and effectiveness are insufficient
Solution Approach 1:
The patent modifies the chemical structure of MDL-A by changing specific parameters such as substituting aromatic rings with heterocyclic groups (pyridine, pyrimidine, triazole), adding fluorine atoms at specific positions, and modifying side chains. These parameter changes in molecular structure lead to improved binding affinity and potency while maintaining the core inhibitory mechanism against IL-6/gp130 interaction.
Solution Approach 2:
The patent creates composite molecular structures by combining the core MDL-A scaffold with various heterocyclic moieties and substituent groups. These composite structures integrate multiple functional elements that work synergistically to enhance inhibitory effectiveness, selectivity, and pharmacological properties while overcoming the limitations of the parent compound.
2Adaptability or versatility
If non-specific inhibitors like SC144 are used, then broad inhibition is achieved, but specificity for IL-6 pathway is lost leading to off-target effects
Solution Approach 1:
The patent introduces specific local modifications to the inhibitor structure that target the unique spatial and chemical features of the IL-6/gp130 binding interface. By optimizing local interactions at specific binding pockets through heterocyclic substitutions and directed group orientations, the compounds achieve high specificity for the IL-6 pathway while sparing other cytokine receptors, thereby reducing off-target immunosuppressive effects.
3Object-affected harmful factors
If IL-6 signaling is inhibited to treat cancer and inflammation, then pathological conditions are addressed, but beneficial immune responses may be suppressed
Solution Approach 1:
The patent employs compounds that replicate the selective inhibitory action of naturally occurring proteins like sIL-6R and soluble gp130, which specifically block pathological IL-6 signaling while preserving other immune functions. By copying the selectivity mechanism of these natural regulators through rational drug design, the compounds achieve therapeutic inhibition of cancer and inflammation without broad immunosuppression.
Data Source
AI summary
The instant invention describes compounds having IL-6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by IL-6.